Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.

@article{Wills1996ShorttermRH,
  title={Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.},
  author={Peter J Wills and Theresa Wodehouse and Kevin Corkery and Kerry Mallon and Rebecca F. Wilson and Peter J. Cole},
  journal={American journal of respiratory and critical care medicine},
  year={1996},
  volume={154 2 Pt 1},
  pages={413-7}
}
We report a double blind placebo-controlled phase II study of the efficacy and safety of nebulized recombinant human DNase (rhDNase) administered for 14 d to adults with bronchiectasis not caused by cystic fibrosis. All were in a stable clinical state at the commencement of the study, and they received (1) rhDNase 2.5 mg twice daily, (2) rhDNase once daily, or (3) placebo (excipient only) inhalation. The outcome measures were spirometry, subjective quality of life/dyspnea, and safety. We also… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…